Hardisontucker8945

1; 95% CI 1.2-3.6; p= 0.007). Addition of belimumab to ST independently protected against adverse SF-36 general health (OR 0.8; 95% CI 0.6-1.0; p= 0.025) and FACIT-F < 30 (OR 0.8; 95% CI 0.6-1.0; p= 0.018).

Overweight and obesity contributed to adverse physical and mental HRQoL outcomes after therapeutic intervention in SLE patients, and underweight contributed to adverse mental HRQoL outcome. A protective effect of belimumab against adverse general health and severe fatigue was implicated.

Overweight and obesity contributed to adverse physical and mental HRQoL outcomes after therapeutic intervention in SLE patients, and underweight contributed to adverse mental HRQoL outcome. A protective effect of belimumab against adverse general health and severe fatigue was implicated.

Metalloproteinase (MMP)-3 and MMP-12 are proteolytic enzymes especially implicated in joint inflammation. This study aims to evaluate their association with arthritis features and hand MRI abnormalities in patients with systemic lupus erythematosus (SLE).

Fifty SLE patients, with a mean (SD) age of 48.1 (14.6) years were tested for MMP-3 and MMP-12 serum levels, then further classified according to the presence of X-Ray erosions and joint deformities. Eighteen rheumatoid arthritis patients aged 47.9 (11.8) and 14 healthy people aged 46.0 (11.0) were enrolled as control groups. A subgroup of 28 SLE patients underwent a dominant-hand MRI; the detected changes were classified and semiquantitatively scored as capsular swelling, synovitis, edematous or proliferative tenosynovitis, bone oedema, bone erosions. Statistical analysis was performed using multiple regression models.

MMP-3 were significantly higher in patients with Jaccoud's arthropathy (JA) (22.1 ng/ml, p< 0.05) and independently associated with hsCRP serum levels (B-coeff 0.50; r = 0.30; p< 0.05). https://www.selleckchem.com/products/gyy4137.html MMP-12 serum levels were significantly lower in patients with JA (0.18 ng/ml, p< 0.05) and inversely associated with the prednisone daily dose (B-coeff -0.03; r= -0.44; p< 0.01). Capsular swelling and edematous tenosynovitis, the most prevalent hand MRI changes in patients with JA, associated with higher MMP-3 (B-coeff 0.12; r = 0.66; p< 0.01 and B-coeff 0.08; r = 0.59; p< 0.01, respectively) and lower MMP-12 serum levels (B-coeff -7.4; r= -0.50; p< 0.05 and B-coeff -5.2; r= -0.44; p= 0.05, respectively).

Imbalanced MMP-3 and MMP-12 serum levels are influenced by inflammation and glucocorticoids in SLE patients and associated with JA and distinctive hand MRI changes.

Imbalanced MMP-3 and MMP-12 serum levels are influenced by inflammation and glucocorticoids in SLE patients and associated with JA and distinctive hand MRI changes.

Central nervous system (CNS) demyelinating syndromes occurring in the context of systemic lupus erythematosus (SLE) may represent a manifestation of neuropsychiatric lupus, or an overlap of SLE and multiple sclerosis (MS). We evaluated prospectively patients presenting with demyelinating syndrome for clinical and serologic evidence of SLE and characterized the evolution of their clinical syndrome to a defined disease.

Patients with CNS demyelinating syndromes not fulfilling the criteria for MS were evaluated in a rheumatology unit for features of SLE and followed longitudinally (enrolment period 2016-2020). Clinical, laboratory and neuroimaging data were recorded at every visit, following multidisciplinary evaluation. At end of follow-up, patients were assessed for their final neurologic and rheumatologic diagnosis and classified accordingly.

79 patients were included in the study [91.1% female, mean (SD) age at first demyelinating episode 38.4 (10.3), median (IQR) observation period 39 (57) months]. Attures (DAF).

Our objective was to determine whether initiation of febuxostat during an acute gout flare prolongs the current episode.

In this randomized, placebo-controlled, single-blinded, multicentre trial, patients with acute gout flares within 72 h were randomized (11) to the placebo and febuxostat (40 mg/day) groups. All patients were administered Diclofenac (150 mg/day) for 7 days and then open-labelled on the 8th day. Febuxostat 40 mg daily and Diclofenac 75 mg daily were administered from day 8 through 28 for the remission period. The dose of diclofenac was 150 mg/day before remission in both arms, and the original protocol was maintained until remission. The primary outcome was "days to resolution".

We randomized 140 patients, 70 into each arm. The mean days to resolution was 5.98 days (median 7.00, IQR 2.45 days) for the placebo and 6.50 days (median 7.00, IQR 3.67 days) for the febuxostat group (p= 0.578). The rate of resolution within 7 days was 84.38% for the placebo group and 76.92% for the febuxostat group (p= 0.284).There were no statistically significant differences in joint pain, swelling, tenderness, and erythema scores at days 1, 3, 5, and 7. The mean serum uric acid levels were 507.54 and 362.62 μmol/l for the placebo and febuxostat group respectively on day 7 (p= 0.000). The rate of recurrent gout flares was 10.00% for the placebo group and 6.56% for the febuxostat group from day 8 through 28 (p= 0.492).

Initiation of febuxostat administration during an acute gout flare did not prolong the duration of acute flares.

Chinese Clinical Trial Registry, http//www.chictr.org.cn/, ChiCTR1800015962.

Chinese Clinical Trial Registry, http//www.chictr.org.cn/, ChiCTR1800015962.

To identify factors associated with fibromyalgia (FM) development and recovery in patients with axial spondyloarthritis (axSpA).

The British Society of Rheumatology Biologics Register (BSRBR-AS) recruited patients with axSpA from 83 centres, in a prospective study. FM was diagnosed using the self-reported Fibromyalgia Survey Diagnostic Criteria (FM-criteria) from 2015. Measures of axSpA disease activity and clinical findings were recorded at regular intervals. We identified predictors for FM development and recovery between yearly visits using uni- and multivariable logistic regression models.

Eight hundred and one participants, 247 (30.8%) female, had two or more visits and were eligible for inclusion. 686 participants did not have FM at baseline, of whom 45 had developed FM at follow-up. 115 participants had FM at baseline, of whom 77 had recovered at follow-up. High baseline Bath Ankylosing Disease activity Index (OR 1.27, 95% CI 1.08-1.49) and Widespread pain index (WPI) (OR 1.14, 95% CI 1.02-1.28) were significantly associated withFM development in the final multivariable model.